TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Normalisation of sitting DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Integrated plasma acylated ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Detection of chromosome abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of decisions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of retrieved oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: pregnancy rate per retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: number of children born alive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Plasma irisin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV16 seroreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Joint pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ability to perform daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stiffness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean total costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained headache and pain-free response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative stool output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diarrhea resolution within 6 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lip mobility improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Disability Index improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean D2/D3 receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of pulmonary valve regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pressure ulcers at two years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acute electrical isolation of all pulmonary veins and freedom from recurrent symptomatic atrial arrhythmia off all antiarrhythmic drugs at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in weekly alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FVII Ag concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Day-10 rates of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Day-10 infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Block success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to onset of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function changes (FVC, FVC%, FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pain level using the visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life according to Oswestry Disability Index score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in clinical symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shorter treatment period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of nosocomial pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: morning stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean return to normal life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients free of atrial tachycardia/atrial fibrillation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Isocentre positioning within 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Displacement >= 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of difficult deliveries
Endpoint domain: Mortality/survival
Primary endpoint: mean cost of intrapartum care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: incremental cost per difficult delivery prevented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intraoperative serum potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial damage
Endpoint domain: Adverse events/effects
Primary endpoint: HLA Class I alloimmunization
Endpoint domain: Adverse events/effects
Primary endpoint: EPCs change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uptake of counselling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: arrythmogenic peri-infarct region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hematoma volume to tumor volume ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral neck BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: index follow-up rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percentage of traceable sexual contacts attending
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ocular Complication Rate (OCR)
Endpoint domain: Adverse events/effects
Primary endpoint: Erythema formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Locoregional Failure-Free Survival (LRFS)
Endpoint domain: Mortality/survival
Primary endpoint: end-inspiratory plateau airway pressure (Pplat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PaO(2)/FIO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: median delay to recovery from paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rate of duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Best-corrected visual acuity mean letter score gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epileptiform discharges (EPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical seizures
Endpoint domain: Adverse events/effects
Primary endpoint: BIS score variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Translational and rotational deviations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol use problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: condom use self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median logMAR visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alpha-GST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: ACR 20% response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life‐Bronchiectasis‐Respiratory Symptoms Score at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Insulin exposure profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic activity (GIRmax and GIR-AUC0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fall in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean sustained adequate relief score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of heartburn episodes with sustained adequate relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: finish sprint speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mild pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cervical width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications and failure rates
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in acne treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two- and 3-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: GAAS success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decrease in all lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum NfL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean gastric-emptying half-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of days free of nausea
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Volume of uterine myomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine artery pulsatility index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increase in plasma BDNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth color change immediately after treatment (ΔE1_0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth color change 24 hours after treatment (ΔE2_0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hydroxylysylpyridinoline and lysylpyridinoline excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new-onset breast discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptance of repeat procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall discomfort, pain, gagging, and belching
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median survival with musculoskeletal symptoms
Endpoint domain: Mortality/survival
Primary endpoint: Median pain 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for morphine rescue
Endpoint domain: Adverse events/effects
Primary endpoint: fluoroscopic time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Breast cancer-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Tumor response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hazard rate of relapse
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of infectious conjunctivitis
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness against Chlamydia trachomatis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of noninfectious conjunctivitis
Endpoint domain: Adverse events/effects
Primary endpoint: Body mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful intubation at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophil count in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-4 expression in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-5 expression in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dyspnea score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dignity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: combined symptom-rescue medication scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Volume (PV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vulvar erythema scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: labial and perineal skin moisture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: efficacy in treating thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduction in intravenous drip of platelets
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reduction in risk of hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CES-D scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean glycosylated hemoglobin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal confirmed hypoglycemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean diurnal decrease in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a mean diurnal percent reduction in IOP of more than 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving an IOP of less than 18 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-Traumatic Stress (PTS) symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ED50 of the initial dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from complementary dose to 25% recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution at steady-state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS-drug liking scores at Emax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete resolution of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABC‐C Irritability Subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of CR002
Endpoint domain: Adverse events/effects
Primary endpoint: Temporary Threshold Shift (TTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular global longitudinal strain (LV GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular global longitudinal strain (RV GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to WBC < 10 G/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to CRP < 100 mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2-pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low-density lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal carbohydrate loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in ADAS-Cog total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inotropic support requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Remifentanil dose adjustments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in patient pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary PC-1 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary NAGA excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum APN activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Opioid withdrawal symptoms (SOWS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone-to-implant contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sealant retention rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of molars with dentine caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molar survival rate (no development of dentine caries)
Endpoint domain: Mortality/survival
Primary endpoint: incidence of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to meet discharge home criteria
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean increase in Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hb response (increase > or =2 g/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MIBI-uptake ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MIBI-perfusion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall response (decrease in Crohn's disease activity index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median duration of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vibration Perception Threshold (VPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of (C)ce(s) haplotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to study discontinuation due to a mood event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to study discontinuation for any reason
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of 5-HT2A inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of obstructive sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of serum cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in BMD of the femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intergroup conflict experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: peak insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: appetite responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body self esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DQST score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypotensive response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes